Data exclusivity is a regulatory period during which authorities cannot rely on originator test data to approve competing products.

In practice

It is most visible in pharmaceuticals and agrochemicals, where clinical or safety data submitted by originators receives time-limited protection from reliance.

IP-services relevance

Although not a patent right, data exclusivity affects entry timing, market structure and service procurement in health-related sectors.

Examples

• A generic launch is delayed because the reliance period has not expired.
• A biologic follow-on strategy accounts for both patent and data timelines.
• Public purchasers face higher short-term costs during exclusivity windows.